LENZ Therapeutics (LENZ) Operating Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Operating Expenses data on file, last reported at $46.0 million in Q1 2026.

• Quarterly Operating Expenses rose 171.9% year-over-year to $46.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $139.3 million (up 134.35% YoY) and the FY2025 annual result came in at $110.2 million, up 88.07% from the prior year.
• Operating Expenses climbed to $46.0 million in Q1 2026 per LENZ's latest filing, from $40.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $46.0 million in Q1 2026 and bottomed at $12.6 million in Q1 2023.
• The 5-year median for Operating Expenses is $21.9 million (2025), against an average of $23.1 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 177.09%; it then plunged 51.4% in 2023.
• Tracing LENZ's Operating Expenses over 5 years: stood at $26.8 million in 2022, then dropped by 6.59% to $25.0 million in 2023, then sank by 39.07% to $15.2 million in 2024, then jumped by 163.06% to $40.1 million in 2025, then rose by 14.94% to $46.0 million in 2026.
• Per Business Quant, the three latest LENZ Operating Expenses figures stand at $46.0 million (Q1 2026), $40.1 million (Q4 2025), and $31.4 million (Q3 2025).

Peer Comparison